Despite my optimism about the long-term prospects of curative gene therapy and CRISPR Therapeutics (NASDAQ:CRSP) stock, a sense of pragmatism and potentially a reality check are in order. Noting the necessary development of treatment centers and the need for more long-term data to encourage greater treatment adoption, I accept that CRISPR stock may not take off for some time. Nonetheless, I remain bullish, given the company’s leading position in the gene-editing space.
CRISPR Therapeutics: The Opportunity
CRISPR Therapeutics has developed life-changing treatments for genetic diseases affecting millions of people worldwide. Its first marketable product, CASGEVY is a gene therapy for sickle cell disease (SCD) and beta-thalassemia, which impacts over 300,000 newborns annually. Not all these people have severe forms of illness, which can be debilitating and disproportionately impact those of African heritage.
The treatment employs…
